You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Johnson and Johnson
AstraZeneca
Baxter
Express Scripts

Last Updated: March 1, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LANSOPRAZOLE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lansoprazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00149084 Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status Yokoyama Foundation for Clinical Pharmacology Phase 3 2003-04-01 The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00149084 Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status Hamamatsu University Phase 3 2003-04-01 The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00174928 A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease Completed Takeda Phase 1 2005-05-01 The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lansoprazole

Condition Name

Condition Name for Lansoprazole
Intervention Trials
Healthy 13
Helicobacter Pylori Infection 11
Gastroesophageal Reflux Disease 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lansoprazole
Intervention Trials
Gastroesophageal Reflux 29
Esophagitis 20
Ulcer 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lansoprazole

Trials by Country

Trials by Country for Lansoprazole
Location Trials
United States 280
Japan 271
China 78
Korea, Republic of 27
Taiwan 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lansoprazole
Location Trials
Missouri 13
California 13
Florida 12
Arizona 12
Texas 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lansoprazole

Clinical Trial Phase

Clinical Trial Phase for Lansoprazole
Clinical Trial Phase Trials
Phase 4 48
Phase 3 43
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lansoprazole
Clinical Trial Phase Trials
Completed 79
Recruiting 25
Not yet recruiting 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lansoprazole

Sponsor Name

Sponsor Name for Lansoprazole
Sponsor Trials
Takeda 35
AstraZeneca 10
National Taiwan University Hospital 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lansoprazole
Sponsor Trials
Other 113
Industry 87
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Baxter
Boehringer Ingelheim
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.